Literature DB >> 29926386

CXCL12 chemokine and CXCR4 receptor: association with susceptibility and prognostic markers in triple negative breast cancer.

Alda Losi Guembarovski1, Roberta Losi Guembarovski2,3, Bruna Karina Banin Hirata4, Glauco Akelinghton Freire Vitiello4, Karen Mayumi Suzuki4, Mayara Tiemi Enokida4, Maria Angelica Ehara Watanabe4, Edna Maria Vissoci Reiche1.   

Abstract

CXCL12/CXCR4 signaling has been implicated in breast carcinogenesis, and genetic polymorphisms in these molecules have been associated with different types of cancer. The present study analyzed genetic polymorphisms in CXCL12 (rs1801157, G > A) and CXCR4 (rs2228014, C > T) and CXCR4 immunostaining in tumor tissues from patients with triple negative breast cancer (TNBC) aiming to evaluate their possible role in its' susceptibility and prognosis. Genetic polymorphisms were analyzed in 59 TNBC patients and 150 control women; age-adjusted logistic regression showed no association when variants were considered in isolation; however, a statistically significant interaction was noted for heterozygosis for both allelic variants increasing the odds for TNBC (CXCL12-GA by CXCR4-CT: OR 7.23; 95% CI 1.15-45.41; p = 0.035). CXCL12 polymorphism was correlated negatively with proliferation index (Ki67) (Tau-b = - 0.406; p = 0.006). CXCR4 immunostaining was evaluated in 37 TNBC patients (22 with paired tumor-normal adjacent tissue). CXCR4 was detected more intensely in cell cytoplasm than in membrane, and was more expressed in tumor than in normal adjacent tissues, although not statistically significant. CXCR4 expression on the membrane of tumor cells was correlated positively with histopathological grade (Tau-b = 0.271; p = 0.036) and negatively with lymph node metastasis (Tau-b = - 0.478; p = 0.036). The present study indicates that CXCL12 and CXCR4 polymorphisms and CXCR4 immunostaining might have susceptibility and prognostic roles in TNBC pathogenesis.

Entities:  

Keywords:  CXCL12; CXCR4; Genetic polymorphism; Immunohistochemistry; Prognosis; Triple-negative breast cancer

Mesh:

Substances:

Year:  2018        PMID: 29926386     DOI: 10.1007/s11033-018-4215-7

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  54 in total

1.  Triple-negative breast cancer: unique biology and its management.

Authors:  Rodrigo O B Maegawa; Shou-Ching Tang
Journal:  Cancer Invest       Date:  2010-10       Impact factor: 2.176

2.  CXCR4 polymorphisms and HIV-1 pathogenesis.

Authors:  M P Martin; M Carrington; M Dean; S J O'Brien; H W Sheppard; S A Wegner; N L Michael
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1998-12-01

3.  Exomic variants of an elderly cohort of Brazilians in the ABraOM database.

Authors:  Michel Satya Naslavsky; Guilherme Lopes Yamamoto; Tatiana Ferreira de Almeida; Suzana A M Ezquina; Daniele Yumi Sunaga; Nam Pho; Daniel Bozoklian; Tatiana Orli Milkewitz Sandberg; Luciano Abreu Brito; Monize Lazar; Danilo Vicensotto Bernardo; Edson Amaro; Yeda A O Duarte; Maria Lúcia Lebrão; Maria Rita Passos-Bueno; Mayana Zatz
Journal:  Hum Mutat       Date:  2017-05-03       Impact factor: 4.878

4.  Stromal cell-derived factor-1 (SDF-1) alleles and susceptibility to breast carcinoma.

Authors:  Mahboobeh Razmkhah; Abdul-Rasoul Talei; Mehrnoosh Doroudchi; Tahereh Khalili-Azad; Abbas Ghaderi
Journal:  Cancer Lett       Date:  2004-12-13       Impact factor: 8.679

5.  A gene expression signature associated with metastatic cells in effusions of breast carcinoma patients.

Authors:  Virginie N Dupont; David Gentien; Marine Oberkampf; Yann De Rycke; Nathalie Blin
Journal:  Int J Cancer       Date:  2007-09-01       Impact factor: 7.396

6.  CXCL12 rs1801157 polymorphism in patients with breast cancer, Hodgkin's lymphoma, and non-Hodgkin's lymphoma.

Authors:  Karen Brajão de Oliveira; Julie Massayo Maeda Oda; Julio Cesar Voltarelli; Thiago Franco Nasser; Mario Augusto Ono; Thiago Cezar Fujita; Tiemi Matsuo; Maria Angelica Ehara Watanabe
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

7.  Plasma stromal cell-derived factor-1: host derived marker predictive of distant metastasis in breast cancer.

Authors:  Saima Hassan; Andrea Baccarelli; Ombretta Salvucci; Mark Basik
Journal:  Clin Cancer Res       Date:  2008-01-15       Impact factor: 12.531

8.  HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants.

Authors:  Lucas D Ward; Manolis Kellis
Journal:  Nucleic Acids Res       Date:  2011-11-07       Impact factor: 16.971

9.  Variant rs1801157 in the 3'UTR of SDF-1ß does not explain variability of healthy-donor G-CSF responsiveness.

Authors:  Miriam Schulz; Darja Karpova; Gabriele Spohn; Annette Damert; Erhard Seifried; Vera Binder; Halvard Bönig
Journal:  PLoS One       Date:  2015-03-24       Impact factor: 3.240

View more
  4 in total

1.  CXCL12/CXCR4 axis gene variants contribute to an increased vulnerability to HPV infection and cervical oncogenesis.

Authors:  Nádia Calvo Martins Okuyama; Fernando Cezar-Dos-Santos; Kleber Paiva Trugilo; Aline Esposito; Roberta Losi Guembarovski; José d'Oliveira Couto-Filho; Maria Angelica Ehara Watanabe; Karen Brajão de Oliveira
Journal:  J Cancer Res Clin Oncol       Date:  2022-01-27       Impact factor: 4.553

2.  Tissue immunostaining of candidate prognostic proteins in metastatic and non-metastatic prostate cancer.

Authors:  Érica Romão Pereira; Laís Capelasso Lucas Pinheiro; Amanda Letícia Francelino; Carlos Alberto Miqueloto; Alda Fiorina Maria Losi Guembarovski; Karen Brajão de Oliveira; Paulo Emílio Fuganti; Ilce Mara de Syllos Cólus; Roberta Losi Guembarovski
Journal:  J Cancer Res Clin Oncol       Date:  2022-08-25       Impact factor: 4.322

3.  High Cytoplasmic CXCR4 Expression Predicts Prolonged Survival in Triple-Negative Breast Cancer Patients Treated with Adjuvant Chemotherapy.

Authors:  Bobae Shim; Min-Sun Jin; Ji Hye Moon; In Ae Park; Han Suk Ryu
Journal:  J Pathol Transl Med       Date:  2018-10-01

4.  Novel role of BRCA1 interacting C-terminal helicase 1 (BRIP1) in breast tumour cell invasion.

Authors:  Balsam Rizeq; Saïd Sif; Gheyath K Nasrallah; Allal Ouhtit
Journal:  J Cell Mol Med       Date:  2020-09-05       Impact factor: 5.310

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.